A51 is a biotechnology company building a technology stack that programs RNA molecules to reprogram cellular states. The company develops programmable RNA as a controllable interface for cell behavior. It is headquartered in Paris, France, was founded in 2025, and has co-founders CEO Marina Katava and CTO Viktor Wendelin Zahoransky.